Abstract: OBJECTIVE To investigate the characteristics, related factors and clinical outcomes of atorvastatin-related myopathy so as to provide a basis of clinical rational drug use. METHODS The age, sex, daily dose, medication time of adverse drug reaction, combined medication, underlying disease, clinical manifestations, alteration of creatine kinase(CK), clinical manifestations as well as prognosis were analyzed by searching CNKI and Wanfang databases. RESULTS A total of 38 case reports included 41 case patients of atorvastatin-related myopathy were reported. The incidence of men(60.98%) was significantly higher than that of women. People older than 70 years(68.29%) were at high risk of developing myopathy. The first two months of initial medication or combined with other drugs was the high-risk period of myopathy. The initial symptoms of myopathy focus on fatigue, myalgia; hematuria/brown urine/brown red urine, nausea/appetite were occasional; convulsions, yellow skin stains, rare fever, palpitation, local swelling were rare. CONCLUSION The occurrence of atorvastatin associated myopathy in severe cases can lead to fatal events. Strengthen the use of education to avoid the self-addition of drugs, and pay attention to the symptoms of myopathy. Closely monitor the changes of liver and kidney function and CK within 1 to 2 months after the use of drugs. Once suspected related myopathy symptoms or elevation of CK, the patients should be given timely medical treatment to avoid the occurrence of fatal events.